Bluefin Capital Management’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $625K | Sell |
10,300
-87,198
| -89% | -$5.08M | 0.4% | 43 |
|
|
2025
Q4 | $5.26M | Buy |
+97,498
| New | +$4.69M | 1.3% | 11 |
|
|
2025
Q3 | – | Sell |
-21,200
| Closed | -$990K | – | 20 |
|
|
2025
Q2 | $981K | Sell |
21,200
-500
| -2% | -$24.5K | 0.74% | 28 |
|
|
2025
Q1 | $1.32M | Buy |
+21,700
| New | +$1.26M | 0.96% | 20 |
|
|
2023
Q1 | – | Sell |
-8,050
| Closed | -$579K | – | 264 |
|
|
2022
Q4 | $579K | Buy |
8,050
+800
| +11% | +$60.3K | 0.09% | 128 |
|
|
2022
Q3 | $515K | Sell |
7,250
-72,888
| -91% | -$5.29M | 0.05% | 184 |
|
|
2022
Q2 | $6.27M | Buy |
80,138
+64,138
| +401% | +$4.88M | 0.69% | 30 |
|
|
2022
Q1 | $1.17M | Sell |
16,000
-30,063
| -65% | -$2.02M | 0.11% | 112 |
|
|
2021
Q4 | $2.87M | Sell |
46,063
-1,058
| -2% | -$62.1K | 0.2% | 91 |
|
|
2021
Q3 | $2.79M | Sell |
47,121
-4,362
| -8% | -$287K | 0.28% | 69 |
|
|
2021
Q2 | $3.44M | Buy |
51,483
+19,430
| +61% | +$1.27M | 0.22% | 76 |
|
|
2021
Q1 | $2.02M | Sell |
32,053
-37,995
| -54% | -$2.36M | 0.09% | 114 |
|
|
2020
Q4 | $4.34M | Buy |
+70,048
| New | +$4.31M | 0.25% | 56 |
|
|
2020
Q3 | – | Hold |
0
| – | – | – | 163 |
|
|
2020
Q2 | – | Sell |
-16,081
| Closed | -$962K | – | 401 |
|
|
2020
Q1 | $896K | Sell |
16,081
-268,673
| -94% | -$16.4M | 0.12% | 134 |
|
|
2019
Q4 | $18.3M | Buy |
284,754
+230,754
| +427% | +$13.2M | 1.21% | 16 |
|
|
2019
Q3 | $2.74M | Buy |
54,000
+49,000
| +980% | +$2.3M | 0.4% | 47 |
|
|
2019
Q2 | $227K | Sell |
5,000
-58,083
| -92% | -$2.71M | 0.03% | 214 |
|
|
2019
Q1 | $3.01M | Buy |
+63,083
| New | +$3.14M | 0.44% | 41 |
|
|
2018
Q1 | – | Sell |
-5,230
| Closed | -$320K | – | 427 |
|
|
2017
Q4 | $320K | Buy |
+5,230
| New | +$327K | 0.02% | 292 |
|
|
2017
Q1 | – | Sell |
-23,894
| Closed | -$1.4M | – | 486 |
|
|
2016
Q4 | $1.4M | Sell |
23,894
-21,106
| -47% | -$1.15M | 0.09% | 123 |
|
|
2016
Q3 | $2.43M | Buy |
+45,000
| New | +$2.89M | 0.09% | 62 |
|
|
2016
Q2 | – | Sell |
-3,344
| Closed | -$236K | – | 505 |
|
|
2016
Q1 | $214K | Sell |
3,344
-10,127
| -75% | -$639K | 0.02% | 293 |
|
|
2015
Q4 | $927K | Buy |
+13,471
| New | +$890K | 0.07% | 238 |
|
|
2015
Q3 | – | Sell |
-4,771
| Closed | -$317K | – | 497 |
|
|
2015
Q2 | $317K | Sell |
4,771
-68,036
| -93% | -$4.48M | 0.02% | 348 |
|
|
2015
Q1 | $4.7M | Sell |
72,807
-5,648
| -7% | -$354K | 0.43% | 63 |
|
|
2014
Q4 | $4.63M | Buy |
78,455
+72,474
| +1,212% | +$4.09M | 0.28% | 76 |
|
|
2014
Q3 | $306K | Sell |
5,981
-7,403
| -55% | -$370K | 0.02% | 498 |
|
|
2014
Q2 | $600K | Buy |
13,384
+105
| +0.8% | +$5.17K | 0.03% | 398 |
|
|
2014
Q1 | $700K | Sell |
13,279
-5,421
| -29% | -$288K | 0.04% | 266 |
|
|
2013
Q4 | $994K | Buy |
+18,700
| New | +$953K | 0.08% | 206 |
|
|
2013
Q3 | – | Sell |
-10,421
| Closed | -$500K | – | 428 |
|
|
2013
Q2 | $500K | Buy |
+10,421
| New | +$452K | 0.05% | 302 |
|
Other funds holding BMY
VCM
VPM
Bluefin Capital Management's BMY Position: Q1 2026 in Review
Bluefin Capital Management reduced its Bristol-Myers Squibb (BMY) stake by 89% in Q1 2026, selling an estimated $5.08M and leaving 10,300 shares worth $625K. The position accounts for 0.4% of the portfolio, ranked #43.
Bluefin Capital Management first reported a position in BMY in Q2 2013 and has held it in 31 quarters since. The position peaked at $18.3M in Q4 2019. 2,521 funds tracked by Wall St. Rank hold BMY as of Q1 2026.
- Bluefin Capital Management held 10,300 shares of Bristol-Myers Squibb worth $625K as of Q1 2026.
- Bluefin Capital Management sold 87,198 Bristol-Myers Squibb shares in Q1 2026, an estimated $5.08M.
- Bristol-Myers Squibb made up 0.4% of Bluefin Capital Management's portfolio in Q1 2026, its #43 holding.
- Bluefin Capital Management first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 31 quarters since.
- Bluefin Capital Management's Bristol-Myers Squibb position peaked at $18.3M in Q4 2019.
- 2,521 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.
Based on Bluefin Capital Management's 13F filing for Q1 2026, filed 15 May 2026.